Piershale Financial Group’s Takeda Pharmaceutical TAK Stock Holding History

Piershale Financial Group’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$2.72K	Buy	+173	New	+$2.83K	﹤0.01%	206

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Piershale Financial Group's TAK Position: Q2 2023 in Review

Piershale Financial Group opened a new position in Takeda Pharmaceutical (TAK) in Q2 2023: 173 shares worth $2.72K. The stake represents ﹤0.01% of the portfolio and ranks #206 among its holdings.

310 funds tracked by Wall St. Rank hold TAK as of Q2 2023.

Piershale Financial Group held 173 shares of Takeda Pharmaceutical worth $2.72K as of Q2 2023.
Takeda Pharmaceutical was a new Piershale Financial Group position in Q2 2023.
Takeda Pharmaceutical made up ﹤0.01% of Piershale Financial Group's portfolio in Q2 2023, its #206 holding.
310 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2023.

Based on Piershale Financial Group's 13F filing for Q2 2023, filed 6 Jul 2023.